Canaccord downgraded Regulus (RGLS) to Hold from Buy with a price target of $11, down from $28, after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
- Regulus downgraded to Hold from Buy at JonesResearch
- Regulus Announces Merger Agreement with Novartis
- Regulus to be acquired by Novartis for $7.00 per share in cash
- Promising Phase 1b Results and Favorable Safety Profile Position Regulus’s Farabursen as a Strong Investment in ADPKD Treatment
- Promising Phase 1b Results and Future Prospects Drive Buy Rating for Regulus’s Farabursen